Clarus Therapeutics Holdings, Inc.

First-quarter 2022 revenue was $4 million, up from $2.3 million a year ago, a 72% increase. Gross profit margin was 83% versus 84% in the prior-year period. Operating expenses were $16.9 million versus $12.8 million last year, with sales and marketing at $10.7 million (up 35%), G&A at $5.3 million (up 47%), and R&D at $0.9 million (down 27%). Cash and cash equivalents were $9.1 million as of March 31, 2022. Management said the upsized $30 million offering closed on April 27 and should fund the current operating plan into approximately September 2022.

Bob Dudley’s message centered on commercial momentum and building longer-term value through patent protection, pipeline development, and strategic options. He said JATENZO prescriptions, payer coverage, and conference visibility were improving, and he emphasized the company’s “continued to explore strategic alternatives” to maximize stockholder value. His tone was upbeat but clearly framed by the need to keep extending runway and advancing funded priorities.

Ric Peterson focused on the quarter’s financial progression and the spending required to support JATENZO. He cited revenue of $4 million, gross margin of 83%, operating expenses of $16.9 million, and cash of $9.1 million at quarter-end, then noted the $30 million offering closed after quarter-end. He said that financing extends the operating plan only into approximately September 2022, underscoring the company’s near-term liquidity constraints.

There was no analyst Q&A on the call; the company explicitly said it would not take questions. As a result, the most notable open issues were management’s own comments on runway, funding-dependent pipeline timing, and the ongoing evaluation of strategic alternatives. The call also highlighted planned future FDA action on CLAR-121 orphan designation and the expectation of more data readouts in 2023.